Text or call a human:Text (808) 600-9260Call
CorporateVentureCapital.com

Ypsomed

Corporate venture profile

Parent Ypsomed

This profile covers the startup investments made by Ypsomed, a healthcare company. It invests at the Series C+ stage. Sectors it names: medical devices.

Every figure links to its source

Snapshot

Investment stage: Series C+ to Series C+
Data behind this graphic
Data behind this graphic
ItemValue
Stage rangeSeries C+ to Series C+
SectorsMedical devices
GeographyNorth America, Europe

Sources: S1 CeQur: raises USD 115M Series C5 (new investors incl. Ypsomed Group), 2021-04-13.

Graphic 1 of 1

Investment stage: Series C+ to Series C+

Sources: S1 CeQur: raises USD 115M Series C5 (new investors incl. Ypsomed Group), 2021-04-13.

Download:Report a correction

Where it invests

Geography

Investment regionsS1

Key facts

FactValueStatusSource
Parent companyYpsomedSingle sourceS1
Parent industryHealthcare and life sciencesSingle sourceS1
StatusActiveSingle sourceS1
Capital sourceParent company onlySingle sourceS1
StagesSeries C+ (inferred from announced rounds)EstimateS1

Recent rounds

DateCompanyRoundAmountLed by the firmSource
2021-04-13CeQurSeries C+USD 115MNoS1

Portfolio

Portfolio company named in public sources: CeQur.S1

Official pages

Read the firm's own pages for current information.

Sources

  1. S1CeQur: raises USD 115M Series C5 (new investors incl. Ypsomed Group), 2021-04-13Portfolio company
  2. S2Ypsomed: company siteParent company

Disclaimer and corrections

Not affiliated. This page is not affiliated with, endorsed by or sponsored by Ypsomed or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.

Spotted a mistake? Report a correction.